Formycon AG

XETRA FYB.DE

Formycon AG Price to Sales Ratio (P/S) on January 14, 2025: 12.46

Formycon AG Price to Sales Ratio (P/S) is 12.46 on January 14, 2025, a 17.70% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Formycon AG 52-week high Price to Sales Ratio (P/S) is 13.22 on January 10, 2025, which is 6.13% above the current Price to Sales Ratio (P/S).
Formycon AG 52-week low Price to Sales Ratio (P/S) is 7.83 on April 19, 2024, which is -37.20% below the current Price to Sales Ratio (P/S).
Formycon AG average Price to Sales Ratio (P/S) for the last 52 weeks is 10.54.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

XETRA: FYB.DE

Formycon AG

CEO	Dr. Stefan Glombitza
IPO Date	Jan. 4, 2011
Location	Germany
Headquarters	Fraunhoferstrasse 15
Employees	239
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials. The company is also developing FYB206; and FYB207, an antiviral drug for the treatment of COVID-19. It has a collaboration agreement with Leukocare AG to develop stable formulations for various candidates in its product pipeline. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.

Key trends

Past 5 years